http://orcid.org/0000-0001-5757-8346
References
- Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;8:1248–1259.
- Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780–790.
- Wada NI, Bream JH, Martínez-Maza O, et al. Inflammatory biomarkers and mortality risk among HIV-suppressed men: a multisite prospective cohort study. Clin Infect Dis. 2016;63(7):984–990.
- Hileman CO, Funderburg NT. Inflammation, immune activation, and antiretroviral therapy in HIV. Curr HIV/AIDS Rep. 2017;14(3):93–100.
- Gatell JM, Assoumou L, Moyle G, et al. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS 2017;31(18):2503–2514.
- Martinez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010;24(11):1697–1707.
- Patterson KB, Prince HA, Stevens T, et al. Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure. AIDS 2013;27(9):1413.
- Martínez E, D’Albuquerque PM, Llibre JM, et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS 2012;26(18):2315–2326.
- Silva EF, Charreau I, Gourmel B, et al. Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy. J Infect Dis. 2013;208(6):892–897.
- Lake J, Mccomsey GA, Hulgan T, et al. Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the women, integrase and fat accumulation trial. HIV Med. 2014;15(7):431–441.
- Taiwo BO, Marconi VC, Berzins B, et al. Dolutegravir plus lamivudine maintain HIV-1 suppression through week 48 in a pilot randomized trial. Clin Infect Dis. 2018;66(11):1794–1797.
- Panel on antiretroviral guidelines for adults and adolescents DHHS. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV Web site. https://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed October, 2017.
- Delaney JA, Suissa S. The case-crossover study design in pharmacoepidemiology. Stat Methods Med Res. 2009;18(1):53–65.
- Rossetti B, Montagnani F, De Luca A. Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients. Expert Opin Pharmacother. 2018;19(7):713–738.
- Castley A, Williams L, James I, et al. Plasma CXCL10, sCD163 and sCD14 levels have distinct associations with antiretroviral treatment and cardiovascular disease risk factors. PLoS ONE. 2016;11(6):e0158169.
- Lake J, Currier J, Koteff J, et al. Cardiovascular biomarkers after switching to ABC/DTG/3TC : the STRIVING study. Paper presented at: 23rd Conference on Retroviruses and Opportunistic Infections, 2016; Boston, MA.
- Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev. 2013;26(1):2–18.
- Belmonti S, Lombardi F, Quiros-Roldan E, et al. Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. J Antimicrob Chemother. 2018;73(7):1949–1954.
- Kelesidis T, Jackson N, McComsey GA, et al. Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection. AIDS 2016;30(17):2625–2633.
- Zidar DA, Juchnowski S, Ferrari B, et al. Oxidized LDL levels are increased in HIV infection and may drive monocyte activation. J Acquir Immune Defic Syndr. 2015;69(2):154–160.